<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221815</url>
  </required_header>
  <id_info>
    <org_study_id>IMPROVE</org_study_id>
    <nct_id>NCT04221815</nct_id>
  </id_info>
  <brief_title>IMPact on Revascularization Outcomes of intraVascular Ultrasound Guided Treatment of Complex Lesions and Economic Impact</brief_title>
  <acronym>IMPROVE</acronym>
  <official_title>IMPact on Revascularization Outcomes of intraVascular Ultrasound Guided Treatment of Complex Lesions and Economic Impact (IMPROVE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rebecca Torguson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) has been
      shown in clinical trials, registries, and meta-analyses to reduce recurrent events after PCI.
      This is accomplished by improving the angiographic result with lesion and vessel assessment
      to guide stent selection and implantation and intravascular imaging following stent
      implantation to ensure an adequate treatment endpoint has been achieved. Despite extensive
      literature supporting the use of IVUS in PCI, utilization remains low in the United States.
      An increasing number of high-risk or complex lesions are being treated with PCI and we
      hypothesize that the impact of IVUS in these complex lesions will be of increased importance
      in reducing clinical adverse events while remaining cost effective.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IVUS core lab measures final PCI Minimum Stent Area</measure>
    <time_frame>Intra-procedural</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel failure (TVF) outcomes at 12 months defined as the composite of cardiac death, target vessel related-myocardial infarction (MI), and ischemia-driven target vessel revascularization.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3100</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>IVUS guided PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiographic-guided PCI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eagle Eye Platinum digital IVUS catheter with optional SyncVision</intervention_name>
    <description>IVUS catheter</description>
    <arm_group_label>IVUS guided PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resolute Onyx Drug Eluting Stent</intervention_name>
    <description>Stent</description>
    <arm_group_label>Angiographic-guided PCI</arm_group_label>
    <arm_group_label>IVUS guided PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years at screening

          -  PCI with stent implantation involving a high risk or complex lesion defined as
             involving at least one of the following characteristics:

          -  Chronic total occlusion

          -  In-stent restenosis

          -  Severe coronary artery calcification

          -  Long lesion (≥ 28 mm in length)

          -  Bifurcation lesion (Any Medina class that involves main branch disease with a side
             branch ≥2.0 mm)

          -  Stable angina, unstable angina, or non-ST Elevation myocardial infarction (NSTEMI),
             undergoing PCI of a single or multivessel coronary artery stenosis

          -  PCI performed with either angiography alone, or IVUS guidance used

        Exclusion Criteria:

          -  Subjects with acute ST elevation myocardial infarction (STEMI), or cardiogenic shock

          -  Use of fibrinolytic therapy within 24 hours of PCI

          -  Planned revascularization as a staged procedure

          -  Stent thrombosis

          -  Use of optical coherence tomography (OCT) during the index procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 27, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medstar Health Research Institute</investigator_affiliation>
    <investigator_full_name>Rebecca Torguson</investigator_full_name>
    <investigator_title>Director, Clinical Research Organization</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

